Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 5/20 | 0.47 |
| ▸ | CTSL | P07711 | 4/20 | 0.47 |
| ▸ | CTSB | P07858 | 3/20 | 0.47 |
| ▸ | SYK | P43405 | 1/20 | 0.44 |
| ▸ | P2RX7 | Q99572 | 6/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | CTSK | P43235 | 4/20 | 0.41 |
| ▸ | BACE1 | P56817 | 1/20 | 0.41 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.40 |
| ▸ | STS | P08842 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24940832 | 0.92 | CTSL (0.45) | CTSSCTSLCTSBSYKP2RX7 | |
| SCHEMBL606258 | 0.90 | P2RX7 (0.45) | CTSSCTSLCTSBSYKP2RX7 | |
| SCHEMBL22041814 | 0.89 | CTSB (0.48) | CTSSCTSLCTSBSYKP2RX7 | |
| SCHEMBL22233159 | 0.84 | SYK (0.46) | SYKP2RX7MEN1KMT2ABACE1 | |
| SCHEMBL22981749 | 0.84 | CTSL (0.43) | CTSSCTSLCTSBSYKMEN1 | |
| SCHEMBL21009793 | 0.84 | MEN1 (0.46) | CTSSCTSLCTSBP2RX7MEN1 | |
| SCHEMBL4569995 | 0.83 | CTSS (0.51) | CTSSCTSLCTSBP2RX7MEN1 | |
| SCHEMBL429816 | 0.83 | MEN1 (0.39) | CTSLMEN1KMT2A | |
| SCHEMBL24094564 | 0.83 | CTSB (0.42) | CTSSCTSLCTSBMEN1KMT2A | |
| SCHEMBL28865052 | 0.81 | SYK (0.44) | CTSSCTSLCTSBSYKP2RX7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026085629-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS, COMPOSITIONS COMPRISING THEM AND USES THEREOF | Université de Montréal (CA) | 2026-04-30 | — | — | WO | disclosed |
| CN-111285875-B | Heterocyclic compound, application thereof and pharmaceutical composition containing same | 苏州信诺维医药科技股份有限公司 | 2023-02-03 | — | — | CN | disclosed |
| US-20230026696-A1 | TRPV4 RECEPTOR LIGANDS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2023-01-26 | — | — | US | disclosed |
| EP-4061124-A1 | TRPV4 RECEPTOR LIGANDS | University of Utah Research Foundation (US) | 2022-09-28 | — | — | EP | disclosed |
| CN-115052478-A | TRPV4 receptor ligands | 犹他大学研究基金会 | 2022-09-13 | — | — | CN | disclosed |
| WO-2022087624-A1 | COMPOUNDS AS RAS INHIBITORS AND USES THEREOF | BIOARDIS LLC (US) | 2022-04-28 | — | — | WO | disclosed |
| WO-2021102314-A1 | TRPV4 RECEPTOR LIGANDS | UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) | 2021-05-27 | — | — | WO | disclosed |
| CN-111269229-B | Compound for treating cancer | 苏州信诺维医药科技有限公司 | 2021-02-12 | — | — | CN | disclosed |
| CN-111285875-A | Heterocyclic compound, application thereof and pharmaceutical composition containing same | 苏州信诺维医药科技有限公司 | 2020-06-16 | — | — | CN | disclosed |
| CN-111269229-A | Compound for treating cancer | 苏州信诺维医药科技有限公司 | 2020-06-12 | — | — | CN | disclosed |
| WO-2020114474-A1 | HETEROCYCLIC COMPOUND, APPLICATION THEREOF AND PHARMACEUTICAL COMPOSITION CONTAINING SAME | 苏州信诺维医药科技有限公司 | 2020-06-11 | — | — | WO | disclosed |
| US-20100029609-A1 | BIARYL SULFONAMIDE DERIVATIVES | NOVARTIS AG (CH) | 2010-02-04 | — | — | US | disclosed |
| US-20100029609-A1 | BIARYL SULFONAMIDE DERIVATIVES | NOVARTIS AG (CH) | 2010-02-04 | — | — | US | disclosed |
| US-20100029609-A1 | BIARYL SULFONAMIDE DERIVATIVES | NOVARTIS AG (CH) | 2010-02-04 | — | — | US | disclosed |
| EP-2081888-A1 | N-BIARYL (HETERO) ARYLSULPHONAMIDE DERIVATIVES USEFUL IN THE TREATMENT OF DISEASES MEDIATED BY LYMPHOCYTES INTERACTIONS | Novartis AG (CH) | 2009-07-29 | — | — | EP | disclosed |
| WO-2008028937-A1 | N-BIARYL (HETERO) ARYLSULPHONAMIDE DERIVATIVES USEFUL IN THE TREATMENT OF DISEASES MEDIATED BY LYMPHOCYTES INTERACTIONS | NOVARTIS AG (CH) | 2008-03-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230026696-A1 | TRPV4 RECEPTOR LIGANDS | TRPV4, TRPV2, TRPV3 | CTSS 3184/4885CTSL 3459/4885CTSB 3130/4885 |
| US-20100029609-A1 | BIARYL SULFONAMIDE DERIVATIVES | UGT2B7, CYP3A7, STS | CTSS 655/4885CTSL 1056/4885CTSB 1743/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.